The Dan Lewis Foundation for Brain Regeneration Research Announces 2024 Prize Open for Applications
Dan Lewis Foundation | Winter 2024

The Dan Lewis Foundation for Brain Regeneration Research (the DLF) is happy to announce the 2024 DLF Prize. This $20,000 prize will be awarded to an early career scientist in neuroscience, pharmacology, or biotechnology whose research record and future research plans align closely with one or more of the DLF’s current research priorities. These research priorities are:


  1. Research into pharmacological methods of reactivating or augmenting synaptogenesis
  2. Research into trials of repleting damaged cortex using derived cortical neurons
  3. Research into transcriptomic profiles of cortical neurons during the recovery phase post brain injury
  4. Research furthering the effective design of antisense oligonucleotides and/or other small molecule medicines to down-regulate inhibitors of regeneration in the cortex and spinal cord.


The successful applicant must be an early career scientist in neuroscience, molecular biology, pharmacology, or biotechnology. The “early career scientist” should be within 2-5 years post-completion of their doctoral degree. Full consideration is given to those scientists working in an academic setting (university or non-profit) or commercial setting (e.g., pharmaceutical or biotech company). The application is due March 31, 2024. Full details are available online through the linked application portal below. The winner of the DLF Prize 2024 will be notified in early June 2024.


https://www.danlewisfoundation. org/application-portal   


The winner of the 2023 DLF Prize, Dr. Roei Maimon has focused on stimulating the brain to create new neurons, an important process in mitigating the detrimental effects of neurodegenerative diseases and injuries. Most recently, Dr. Maimon and colleagues designed and executed tests using a certain type of biomolecular “medicines” called antisense oligonucleotides (ASOs) to generate glia-to-neuron conversion in the adult rodent nervous system. These new neurons matured and functionally integrated into endogenous circuits over a two month period, ultimately positively influencing the behavior of the mice.


Dr. Maimon has demonstrated his enthusiasm for the DLF and for the field of brain regeneration research by participating in several DLF activities designed to increase public awareness of our mission. We look forward to meeting the next DLF Prize winner and to supporting the development of young neuroscientists and their accomplishments in the field of brain regeneration.

The word arpah is written in blue letters on a white background.

ARPA-H Announcement Seeks Research Projects in Brain Regeneration

By Dan Lewis Foundation • July 31, 2025
On July 10, 2025, the Advanced Research Projects Agency for Health (ARPA-H) announced a major initiative titled Functional Repair of Neocortical Tissue or FRONT. The announcement states “FRONT will pioneer a curative therapy for the more than 20 million adults in the US living with chronic neocortical brain damage from neurodegeneration, stroke, trauma, and other causes, which costs the country an estimated $800 billion per year. Worldwide, more than 200 million people live with debilitating after-effects of brain damage.”  A set of informational meetings about this program and a due date for outlines of potential proposals have been set for August. Full proposals are due by September 25, 2025. Complete instructions, specifications, and expectations are delineated in the ARPA-H FRONT announcement. The FRONT announcement includes a clear expectation that the successful brain regeneration methods that are discovered will be used in clinical trials with persons with brain injury by the fifth year of the program. The DLF lauds ARPA-H for initiating this program. We are discussing possibilities for playing a supportive role as proposals develop. This exciting program is congruent with the original overarching goals of the DLF and confirms the validity of its mission.
Photo of Dr. Justin Burrell

2025 DLF Prize Awarded to Justin Burrell, Ph.D.

By Dan Lewis Foundation • July 31, 2025
Dr. Burrell is a translational neuroengineer in the Departments of Neurosurgery and Oral & Maxillofacial Surgery at the University of Pennsylvania. His research integrates advanced neural repair strategies with clinical translation, focusing on axon protection, nerve fusion, and engineered neural tissue for neurotrauma recovery. Dr. Burrell has led the development of multiple first-in-field innovations—including the first large-animal model of nerve fusion, delayed axonal fusion protocols, and the first orally active axonal protectants—positioning him as a recognized leader in regenerative neurotechnologies. He is co-founder of Neurostorative LLC and plays a central role in several other platforms aimed at neural reconnection, long-term preservation, and bio-integrated prosthetic systems.